

Published in final edited form as:

J Med Chem. 2009 May 14; 52(9): 2733–2746. doi:10.1021/jm801314f.

Novel, Potent and Radio-Iodinatable Somatostatin Receptor 1 (sst₁) Selective Analogues

Judit Erchegyi^{1,+}, Renzo Cescato^{3,+}, Christy Rani R. Grace^{2,+}, Beatrice Waser³, Véronique Piccand³, Daniel Hoyer⁴, Roland Riek², Jean E. Rivier^{1,*}, and Jean Claude Reubi³

¹The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA ²Structural Biology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA ³Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, CH 3010, Switzerland ⁴Psychiatry/Neuroscience Research, WSJ-386/745, Novartis Institutes for Biomedical Research, Basel, CH 4002 Basel, Switzerland

Abstract

The proposed sst₁ pharmacophore¹ derived from the NMR structures of a family of mono- and dicyclic undecamers was used to design octa-, hepta- and hexamers with high affinity and selectivity for the somatostatin sst₁ receptor. These compounds were tested for their *in vitro* binding properties to all five somatostatin (SRIF) receptors using receptor autoradiography; those with high SRIF receptor subtype 1 (sst₁) affinity and selectivity were shown to be agonists when tested functionally in a luciferase reporter gene assay. Des-AA^{1,4-6,10,12,13}-[DTyr²,DAgl(NMe,2naphthoyl)⁸,IAmp⁹]-SRIF-Thr-NH₂ (**25**) was radio-iodinated (¹²⁵I-**25**) and specifically labeled sst₁-expressing cells and tissues. 3D NMR structures were calculated for des-AA^{1,4-6,10,12,13}-[DPhe²,DTrp⁸,IAmp⁹]-SRIF-Thr-NH₂ (**16**), des-AA^{1,2,4-6,10,12,13}-[DAgl(NMe,2naphthoyl)⁸,IAmp⁹]-SRIF-Thr-NH₂ (**23**) and des-AA^{1,2,4-6,10,12,13}-[DAgl(NMe,2naphthoyl)⁸,IAmp⁹,Tyr¹¹]-SRIF-NH₂ (**27**) in DMSO. Though the analogues have the sst₁ pharmacophore residues at the previously determined distances from each other, the positioning of the aromatic residues in **16**, **23** and **27** is different from that described earlier suggesting an induced fit mechanism for sst₁ binding of these novel, less constrained sst₁-selective family members.

Keywords

somatostatin analogues; radio-iodinatable SRIF analogues; SAR; NMR structures; somatostatin receptor 1 selectivity

Introduction

Somatostatin (SRIF) is a cyclic tetradecapeptide widely distributed throughout the body with important regulatory effects (mostly inhibitory) on a variety of endocrine and exocrine functions. It was originally isolated from the hypothalamus and characterized in 1973.^{2, 3} Somatostatin is also found in the gut, pancreas, in the nervous system, and in various exocrine and endocrine glands. Somatostatin inhibits the release of growth hormone from the anterior

⁺Contributed equally

*Corresponding author: Jean E. Rivier, The Salk Institute, The Clayton Foundation Laboratories for Peptide Biology, 10010 North Torrey Pines Road, La Jolla, CA 92037, (858) 453-4100, Fax: (858) 552-1546, jrivier@salk.edu

pituitary, insulin and glucagon from the pancreas, and gastrin from the gastrointestinal tract. It also has anti-proliferative activity, and acts as a neurotransmitter, or neuromodulator in the brain.⁴⁻⁷

SRIF interacts with five specific receptor subtypes (sst₁ to sst₅) that have been cloned and characterized, all belonging to the G-protein-coupled receptor family.⁸⁻¹⁰ Cell lines recombinantly expressing these cloned receptors are available to test SRIF analogues for binding affinity, selectivity and functional effects.^{7, 11-13} So far, only sst₂ and sst₅ receptors have been clearly linked to specific physiological functions.^{14, 15} For sst₁ receptors, however, the cellular localization as well as the distinct functions are still not fully understood, similarly to our current lack of knowledge of sst₃ or sst₄ receptor function and physiology.


Sst₁ receptors have been found in human cerebral cortex,¹⁶ human retina,¹⁷ neuroendocrine cells,¹⁴ endothelial cells of human blood vessels (arteries and veins)¹⁸ and human tumors.¹⁹⁻²⁴ According to Lanneau²⁵ and Olias,¹⁴ sst₁ receptors are involved in the intrahypothalamic regulation of growth hormone (GH) secretion. The studies of Kreienkamp et al. suggested an important role for sst₁ in the control of basal GH release in somatotrophs.²⁶ Zatelli et al. have demonstrated that sst₁-selective activation inhibits hormone secretion and cell viability in GH- and prolactin-secreting adenomas *in vitro* and suggested that somatostatin analogues with affinity for sst₁ receptors may be useful to control hormone hyper secretion and reduce neoplastic growth of pituitary adenomas.²⁷ Sst₁ receptor activation also modulates somatostatin release in basal ganglia.²⁸ In hypothalamic, basal ganglia, and retinal functions, the sst₁ receptor appears to act as an inhibitory auto-receptor located on somatostatin neurons, whereas in the hippocampus, such a role is still based on circumstantial evidence.

Sst₁-selective analogues could possibly play a role in various diseases. For instance, retinal disease therapeutics has been a suggested indication for sst₁.^{17, 28-30} Recently, an sst₁ antagonist was shown to promote social interactions, reduce aggressive behavior and stimulate learning.^{31, 32} Matrone et al. demonstrated the role of sst₁-selective analogues in mediating the inhibitory effect of SRIF on growth hormone secreting pituitary tumors. They suggested that the sst₁-selective analogues might represent a further useful approach for the treatment of acromegaly in patients resistant or partially responsive to octreotide-LAR or lanreotide treatment *in vivo*.³³ It has also been reported that in medullary thyroid carcinoma, calcitonin secretion and gene expression can be reduced by treatment with sst₁-selective agonists by the reduction of cAMP response element binding phosphorylation, suggesting that potent sst₁-selective agonists could have a therapeutic role in medullary thyroid carcinoma.^{34, 35} Furthermore, since sst₁-selective agonists were able to inhibit endothelial activities, a potential therapeutic utility for administration of sst₁-selective agonists in the proliferative diseases involving angiogenesis has been suggested.¹⁸

Although numerous reports on the localization, physiological and therapeutic functions of sst₁ receptors have been published, it is still not clear which is the main sst₁ receptor function and the main sst₁ related pathology. The design of more potent and more (>100-fold) sst₁-selective agonists and antagonists with radio-labelable properties for *in vitro* binding assays and *in vivo* scintigraphy studies as well as greater metabolic stability in biological fluids than the native hormone could help to further understand sst₁-related biology and pathobiology. Originally, we had identified the first generation of a peptidic scaffold with selected amino acids (AA) deletions (des-AA^{1,2,5}-SRIF) that in combination with DTrp at position 8 and 4-(N-isopropyl)-aminomethylphenylalanine (IAmp) at position 9, yielded des-AA^{1,2,5}-[DTrp⁸,IAmp⁹]-SRIF (CH-275)³⁶ (**2**), (Table 1) a SRIF agonist that was 30-fold more selective for sst₁ versus sst_{2/4/5} and 10-fold versus sst₃, respectively.³⁶ Our standard drug design approaches led to additional very potent sst₁-selective mono- and dicyclic undecapeptides des-AA^{1,2,5}-[DTrp⁸,IAmp⁹, Tyr¹¹]-SRIF (**3**)³⁷, des-AA^{1,2,5}-[DTrp⁸,IAmp⁹, ITyr¹¹]-SRIF (**4**)³⁷,


des-AA^{1,2,5}-[DTrp⁸,IAmp⁹,ITyr¹¹]-Cbm-SRIF (**5**)¹, des-AA^{1,2,5}-cyclo(7-12)
[Glu⁷,DTrp⁸,IAmp⁹,ITyr¹¹,hhLys¹²]-SRIF³⁸(**6**), and des-AA^{1,2,5}-[DAgl(NMe,
2naphthoyl)⁸,IAmp⁹,Tyr¹¹]-SRIF³⁹(**7**) (Table 1).^{1, 37-40}

In several drug design studies of different hypothalamic releasing hormones (gonadotropin-releasing hormone (GnRH),⁴¹ corticotropin-releasing factor (CRF),⁴² SRIF,^{37, 43, 44}), we had demonstrated that substitutions of natural amino acids with betidamino acids were compatible with biological activity. Betidamino acids are monoacylated derivatives of α -aminoglycine. The synthesis of α -Fmoc, β -Boc-aminoglycine was originally described by Qasmi et al.,⁴⁵ and the synthesis of the methylated derivatives was published by our group.⁴⁶ As we demonstrated earlier, the substitution of DTrp⁸ by DAgl(NMe,2naphthoyl)⁸ in the undecamer scaffold³⁷ (**3** versus **7**, Table 1) had resulted in a 5-fold increase in binding affinity at sst₁.³⁹



4-(N-isopropyl)-aminomethylphenylalanine

IAmp



structure of betidamino acid

(R₁ = CH₃; R₂ = 2-naphthyl)

Here, we describe the rational design and optimization of a novel class of peptidic somatostatin sst₁-selective analogues derived from the use of our published sst₁-pharmacophore model.¹

Results and Discussion

Peptide synthesis

All analogues shown in Table 1 were synthesized either manually or automatically on a 4-methylbenzhydrylamine (MBHA) or chloromethylated (CM) resin using the Boc-strategy and *N,N'*-diisopropylcarbodiimide (DIC)/1-hydroxybenzotriazole (HOBt) for amide bond formation.

We used an unresolved aminoglycine (Agl) derivative Fmoc-D/LAgl(NMe,Boc)-OH^{46, 47} as template for the introduction of a betidamino acid in the scaffolds (des-AA^{1,4-6,10,12,13}-SRIF-Thr/Nal-NH₂, des-AA^{1,2,4-6,10,12,13}-SRIF-Thr/Nal-NH₂ and des-AA^{1,2,4-6,10,12,13}-SRIF-NH₂), which resulted in diastereomeric mixtures that were separated by RP-HPLC⁴⁸⁻⁵⁰ and were fully characterized. The absolute configuration of the Agl residue in the diastereomers was deduced from enzymatic hydrolysis studies with aminopeptidase M and proteinase K, respectively. Comparison of the enzymatic cleavage patterns of the diastereomers showed that

the LAgI-containing analogue was hydrolyzed while the DAgl-containing analogue was not.
50

The peptide resins were treated with anhydrous hydrogen fluoride in the presence of scavengers (anisole and dimethylsulfide) to liberate the fully deblocked crude peptides. Cyclization of the cysteines was mediated by iodine in an acidic milieu. Purification was achieved using multiple RP-HPLC steps.⁴⁹ Analytical RP-HPLC,⁴⁹ capillary zone electrophoresis (CZE)⁵¹ and mass spectrometry were used to determine the purity and identity of the analogues.

NMR studies

The NMR samples of **16**, **23** and **27** were prepared by dissolving 2.5 mg of the peptide in 500 μ l of DMSO- d_6 . Assignment of the various proton resonances was carried out using the standard procedure, using DQF-COSY, TOCSY and NOESY experiments. Though **16** showed a single set of resonances for all the protons, two sets of resonances were observed for most of the protons for **23** and **27** in the ratio 60:40, except for the HN and α H resonances of IAmp⁹. This is due to the *cis/trans* isomerization of the amide bond present in the side chain of the betidamino acid DAgl at position 8 of **23** and **27**, as reported earlier.⁵² Almost complete assignment of the chemical shifts of the various proton resonances is carried out for **16**, **23** and **27** and is shown in Table 2A-2C. Amide resonances of Cys³ were not observed for **23** and **27** in the NMR spectra due to fast exchange with the solvent.

A reasonably large number of experimental NOEs is observed for the three analogues in the NOESY spectrum measured with a mixing time of 100 msec, leading to over 70 meaningful distance restraints per analogue (Table 3, Figure 1). For all analogues, structural restraints from NOEs were used as input for the structure calculation with the program CYANA⁵³ followed by restrained energy minimization using the program DISCOVER.⁵⁴ The resulting bundle of 20 conformers per analogue represents the 3D structure of each analogue. For each analogue, the small residual violations in the distance constraints only for the 20 refined conformers (Table 3) and the coincidence of experimental NOEs and short interatomic distances (data not shown) indicate that the input data represent a self-consistent set, and that the restraints are well satisfied in the calculated conformers (Table 3). The deviations from ideal geometry are minimal, and similar energy values were obtained for all 20 conformers of each analogue. The quality of the structures determined is reflected by the small backbone RMSD values relative to the mean coordinates of ~ 0.5 Å (see Table 3 and Figure 2).

Three-dimensional structure of H-DPhe²-c[Cys³-Phe⁷-DTrp⁸-IAmp⁹-Phe¹¹-Cys¹⁴]-Thr¹⁵-NH₂ (16**)**—Analogue **16** binds selectively to sst₁ with moderately high affinity (IC₅₀ \sim 30 nM). It differs from octreotide by IAmp⁹, Phe¹¹ and Thr¹⁵-NH₂ and the 3D NMR structure shows that the backbone has a β -turn of type III' around DTrp⁸ and IAmp⁹ (Figure 2A, Table 4). In all of the calculated 20 conformers, there is a hydrogen bond between the amide protons of Phe¹¹ to the carbonyls of Phe⁷ that stabilizes the β -turn. The side chains of DPhe², Phe⁷ and DTrp⁸ are in the *gauche*⁺ configuration, the side chains of IAmp⁹ and Phe¹¹ are in the *gauche*⁻ configuration (Table 4).

Three-dimensional structure of H-c[Cys³-Phe⁷-DAgl(NMe,2naphthoyl)⁸-IAmp⁹-Phe¹¹-Cys¹⁴]-Thr¹⁵-NH₂ (23**)**—Analogue **23** differs from **16** by the substitution of DTrp⁸ by DAgl(NMe,2naphthoyl)⁸ and the deletion of DPhe² at the N-terminus (Table 1). With those modifications, **23** binds selectively to sst₁ with high affinity (IC₅₀ = 1 nM). The 3D NMR structure of **23** shows that the angles around DAgl(NMe,2naphthoyl)⁸ and IAmp⁹ do not represent any standard β -turns (Figure 2B, Table 4). The side chains of Phe⁷, DAgl(NMe, 2naphthoyl)⁸, IAmp⁹ and Phe¹¹ are in the *gauche*⁻ configuration (Table 4). In addition, the side chains of Phe⁷ and DAgl(NMe,2naphthoyl)⁸ span a large conformational space (Figure 2B,

Table 4). In the major conformer, the side chain methyl protons of DAgl(NMe,2naphthoyl)⁸ give rise to NOE/ROEs to both the H1 and H8 protons of the naphthoyl group suggesting that DAgl(NMe,2naphthoyl)⁸ is in *trans* isomer in the major conformer. Based on the large number of NOEs observed, the 3D NMR structure of the major conformer was calculated and this is assumed to be the bioactive conformation.

Three-dimensional structure of H-c[Cys³-Phe⁷-DAgl(NMe,2naphthoyl)⁸-IAmp⁹-Tyr¹¹-Cys¹⁴]-NH₂ (27)—The composition of **27** is different from that of **23** with Tyr¹¹ replacing Phe¹¹ and the deletion of Thr¹⁵ at the C-terminus (Table 1), yet it binds selectively to sst₁ with high affinity (IC₅₀ = 6 nM). The 3D NMR structure shows that the angles around DAgl(NMe,2naphthoyl)⁸ and IAmp⁹ do not represent any standard β-turns (Figure 2C, Table 4). The side chains of Phe⁷ and Tyr¹¹ are in the *gauche*⁺ configuration, the side chains of DAgl(NMe,2naphthoyl)⁸ and IAmp⁹ are in the *gauche*⁻ configuration (Table 4). The side chains of DAgl(NMe,2naphthoyl)⁸ and IAmp⁹ span a large conformational space (Figure 2C, Table 4). In the major conformer, the side chain methyl protons of DAgl(NMe,2naphthoyl)⁸ give rise to NOE/ROEs to both the H1 and H8 protons of the naphthoyl group suggesting that DAgl(NMe,2naphthoyl)⁸ is in *trans* isomer in the major conformer. Based on the large number of NOEs observed, the 3D NMR structure of the major conformer was calculated and this is assumed to be the bioactive conformation. Moreover, the minor conformer was poorly defined due to the few number of NOEs that could be identified for this conformation.

Biological testing

To determine their SRIF receptor-binding properties, the compounds were tested for their ability to bind to cryostat sections of a membrane pellet of cells expressing the five human SRIF receptor subtypes (Table 1). For each of the tested compounds, complete competition experiments were carried out with the universal SRIF radioligand [Leu⁸,DTrp²²,¹²⁵I-Tyr²⁵] SRIF-28 (¹²⁵I-[LTT]-SRIF-28).⁵⁵ The results are shown in Table 1. The most potent and selective analogues were functionally evaluated for their agonist/antagonist properties using a reporter gene assay that determines the biological activity of the human sst₁ receptor in CCL39-sst₁-Luci cells constitutively expressing the human sst₁ receptor as well as the luciferase gene under the control of the serum response element (SRE). The SRE is regulated by transcription factors and is activated by many extracellular signals including ligands acting at G-protein-coupled receptors.^{56, 57} It has been shown that upon agonist binding, SRIF receptors mediate an increase of luciferase expression via SRE in this reporter gene assay.^{32, 58} Figure 3 shows that stimulating CCL39-sst₁-Luci cells with somatostatin analogues activates the luciferase gene in a concentration-dependant manner. SRIF-14, **23** and **25** exhibit EC₅₀ values of 0.93 nM, 3.9 nM and 0.37 nM, respectively while the sst₁- agonist des-AA^{1,5}-[Tyr²,DTrp⁸,IAmp⁹]-SRIF (CH-288)³⁷ (**33**) exhibits an EC₅₀ value of 33 nM. Des-AA^{1,2,4,5,12,13}[DCys³,Tyr⁷,DAgl⁸(NMe,2naphthoyl)]-Cbm-SRIF (Sst₃-ODN-8)⁴³ (**35**), a short-sized somatostatin analog with no affinity to sst₁ receptor used as negative control was unable to stimulate luciferase gene expression in CCL39-sst₁-Luci cells. The results of the reporter gene assay are summarized in Table 1.

Structure activity relationship studies

The proposed sst₁ receptor pharmacophore¹ derived from the NMR structures of the family of the undecamers (mono and dicyclic)^{37, 38} compared with the previously proposed sst₂, sst_{2,5} and sst₄ pharmacophores are shown in Figure 4.

With a well-defined pharmacophore, we were now in a position to design improved analogues following a rational approach. In this regard, we designed putative sst₁-selective octa-, hepta-, and hexamers derived from the known undecamers.¹ Figure 4A shows that the sst₁-selective agonist-pharmacophore has two aromatic side chains, at position 6 or 7 and 11, in addition to

the DTrp⁸ and IAMP⁹ pair. The sst₁ selectivity is achieved mainly through the amino acid IAMP at position 9, which replaces Lys, present in most of the somatostatin analogues. The side chain of IAMP is longer than the side chain of Lys, it has an aromatic group (aminomethylphenylalanine) extended by a relatively bulky aliphatic group (isopropyl). Hence, we conclude that IAMP cannot be accommodated in a smaller binding pocket that will fit a smaller side chain as that of Lys⁹ critical for sst₂₋₅ binding. We propose that only in the sst₁ receptor structure is the binding pocket large enough to accommodate the side chain of IAMP (comparing the residues in the models of the trans-membrane regions of the somatostatin receptors based on the crystal structure of Rhodopsin) and therefore analogues with IAMP at position 9 show selectivity for sst₁.

We wanted to identify smaller peptidic molecules than the undecamers, which would retain selectivity as well as good affinity at sst₁ receptors and possibly would act as antagonists having greater metabolic stability than the previously published analogues.^{36-39, 59} As we published earlier, the hypothesis that IAMP⁹ by itself might establish sst₁ selectivity in the otherwise potent pan-somatostatin octapeptide des-AA^{1,2,4,5,12,13}-[DTrp⁸]-SRIF (ODT-8)⁵⁰ (**8**) failed (Table 1). Substitution of Lys⁹ in **8** by IAMP⁹ resulted in des-AA^{1,2,4,5,12,13}-[DTrp⁸, IAMP⁹]-SRIF (**9**), which showed no binding affinity to any SRIF receptor,³⁷ most probably due to steric effects perturbing the alignment of the DTrp⁸-IAMP⁹ side chains with respect to the other aromatic side chains.

Since the backbone conformations of the sst₁-selective analogues have a hairpin-like structure similar to that of the sst_{2/3/5}-selective octreotide-based analogues, we decided to introduce IAMP at position 9 in the octreotide scaffold with the additional substitutions (an aromatic side chain at positions 6 or 7 and at position 11) indispensable to fulfill the sst₁ pharmacophore's requirements (see below).

With the aim of searching for sst₁-selective antagonists, we first substituted Lys⁹ with IAMP⁹ in the published sst₂-antagonist des-AA^{1,4-6,11-13}-[Cpa², DCys³, Tyr⁷, DTrp⁸]-SRIF-2Nal-NH₂ (**12**),^{60, 61} which resulted in (des-AA^{1,4-6,11-13}-[Cpa², DCys³, Tyr⁷, DTrp⁸, IAMP⁹]-SRIF-2Nal-NH₂ (**13**) with no binding affinity to sst_{1/4/5} and low binding affinity to sst_{2/3} (ca. 350 nM). Based on the sst₁ pharmacophore, it was expected that the introduction of IAMP alone would not be sufficient for sst₁ binding (Table 1) since **13** does not have two of the aromatic residues at positions 6 or 7 and 11 necessary for sst₁ binding. Though there is an aromatic residue at position 7 in octreotide-based analogues, they do not have Phe at position 11. Hence, we replaced Thr at position 10 by Phe at 11 (as in SRIF), leaving 4 residues and the two Cys residues in the cycle. This analogue (**16**) exhibited similar affinity to sst₁ (IC₅₀ = ~30 nM) as **8** but it is more selective since it shows low affinity to the other four receptors (see Table 1). Therefore analogue **16** was selected as lead for further derivatization.

Our SAR studies focused on positions 2, 3, 8, 9, 11, and 15 of the analogue **16** (SRIF numbering). Affinities to the five SRIF receptors were determined in receptor binding assay and are summarized in Table 1.

SAR at position 2 where DPhe, Cpa, Tyr and DTyr were substituted show that these residues can be eliminated with only small differences in binding affinity to sst₁ (des-AA^{1,2,4-6,10,12,13}-[DTrp⁸, IAMP⁹]-SRIF-Thr-NH₂ (**15**) versus **16**, des-AA^{1,2,4-6,10,12,13}-[DTrp⁸, IAMP⁹, ITyr¹¹]-SRIF-Thr-NH₂ (**17**) versus des-AA^{1,4-6,10,12,13}-[DPhe², DTrp⁸, IAMP⁹, ITyr¹¹]-SRIF-Thr-NH₂ (**18**), des-AA^{1,2,4-6,10,12,13}-[DCys³, DTrp⁸, IAMP⁹, ITyr¹¹]-SRIF-2Nal-NH₂ (**19**) versus des-AA^{1,4-6,10,12,13}-[Cpa², DCys³, DTrp⁸, IAMP⁹, ITyr¹¹]-SRIF-2Nal-NH₂ (**20**), des-AA^{1,2,4-6,10,12,13}-[LAgl (NMe,2naphthoyl)⁸, IAMP⁹]-SRIF-Thr-NH₂ (**24**) versus des-AA^{1,4-6,10,12,13}-[DTyr², LAgl

(NMe,2naphthoyl)⁸,IAmp⁹]-SRIF-Thr-NH₂ (**26**) and des-AA^{1,2,4-6,10,12,13}-[DCys³,DAgl(NMe,2naphthoyl)⁸,IAmp⁹]-SRIF-2Nal-NH₂ (**29**) versus des-AA^{1,4-6,10,12,13}-[Tyr²,DCys³,DAgl(NMe,2naphthoyl)⁸,IAmp⁹]-SRIF-2Nal-NH₂ (**31**). We suggest that the individual nature of these amino acids (despite the fact that their side chains are not involved in binding) is responsible for the differences in affinity. SAR at position 3 suggests that the substitution of Cys with DCys has little effect on sst₁ binding affinity and function. SAR at position 8 shows the unique nature of Agl⁸-containing analogues that are all highly selective for sst₁ over the other four receptor subtypes (**23**, **25**, **27**, **29**). Interestingly, for this scaffold, a D-configuration is significantly more favorable than the L-conformation. SAR at position 9 shows that the introduction of IAmp results in more active and selective analogues (des-AA^{1,4-6,10,12,13}-[Cpa²,DCys³,DAgl(NMe,2naphthoyl)⁸]-SRIF-2Nal-NH₂ (**21**) versus **31**). SAR at position 11 shows that the substitution of Phe as in **15** or **16** with I-Tyr results in some loss in sst₁ binding affinity (**17** and **18**). SAR at position 15 shows that this residue can also be eliminated from some structures without loss of binding affinity and selectivity as in **27**. This deletion along with other most favorable substitutions yielded the hexapeptide H-c [Cys³-Phe⁷-DAgl(NMe,2naphthoyl)⁸-IAmp⁹-Tyr¹¹-Cys¹⁴]-NH₂ (**27**). This peptide selectively binds to sst₁ with an average IC₅₀ = 6.0 nM, (IC₅₀ >1000 nM at sst₂, 317 nM at sst₃, 481 nM at sst₄, and >1000 nM at sst₅, respectively). Compared to our previously published analogues, which contained 11 residues, **27**, containing only 6 residues, is a much smaller and appealing molecule.

Though des-AA^{1,4-6,12,13}-[Tyr²,DTrp⁸,IAmp⁹]-SRIF-Thr-NH₂ (**14**), **15** and **17-20** (Table 1) showed IC₅₀ for sst₁ in the 500 nM range, their binding affinities are significantly lower compared to that of SRIF-28 (IC₅₀ for sst₁ = 2.9 nM), **8** (IC₅₀ for sst₁ = 27 nM) and **5** (IC₅₀ for sst₁ = 2.5 nM).¹ The lower affinities of these analogues could be explained based on the knowledge of the sst₁ pharmacophore and be due to one or more of the following reasons: (1) the distances between the side chains of the residues involved in binding may be slightly different from the distances required by the sst₁ pharmacophore (the distances reported for efficient receptor-ligand interactions are as follows: between DTrp⁸ and IAmp⁹ is 7-8 Å, between DTrp⁸ and Phe^{6/7} is 6-7.5 Å, between DTrp⁸ and Phe¹¹ is 9.5-12 Å, between IAmp⁹ and Phe^{6/7} is 9-11 Å, between IAmp⁹ and Phe¹¹ is 8-10 Å and between Phe^{6/7} and Phe¹¹ is 6-7.5 Å, (Figure 4A)¹) that the side chains possibly occupy the binding pocket partially; (2) the conformational rigidity in the side chain of DTrp at position 8 is in such a way that it cannot occupy completely the available binding pocket; (3) though the analogues have two aromatic residues, the aromatic side chains could be on the front side of the peptide backbone (when displayed from N to the C-terminus) resulting in μM binding affinity.

In the octreotide pharmacophore, the side chains of DTrp⁸ and Lys⁹ are in close proximity (4-6 Å),^{62, 63} (Figure 4C) whereas in the sst₁-pharmacophore the side chains of DTrp⁸ and IAmp⁹ are farther apart (7-8 Å) (Figure 4A). Since the side chain of aminoglycine (Agl) has been shown to span a larger volume than the DTrp side chain, we introduced acylated Agl at position 8.⁵² This substitution in the shortened analogues (**21**, **23**, **25**, **27**, **29** and **31**) improved the binding affinity and selectivity for sst₁ as well. Some of these analogues also exhibit binding to sst₄. The introduction of Phe¹¹ (**21**, **23**, **25**, **29** and **31**) results in an aromatic group close to Lys⁹/IAmp⁹ as well as DTrp/DAgl⁸, which satisfies the sst₄ pharmacophore partially and allows binding (Figure 4D, Table 5).

Following up on the observation by Bass et al.^{64, 65} and Hocart et al.⁶¹ that one could turn an octreotide-based sst₂ agonist scaffold characterized by a DAaa²-LCys³ to an antagonist scaffold characterized by a LAaa²-DCys³, we tested **31** for agonism/antagonism. In our functional luciferase reporter gene assay, **31** along with **23**, **25**, **27** and **29**, were agonists at human sst₁ (Table 1). The best analogue in this series is **25** with an EC₅₀ value of 0.37 nM in the luciferase reporter gene assay, with a binding IC₅₀ of 0.19 nM, and 5,000-fold selectivity

versus sst_{2/5}, 500-fold selectivity versus sst₃, and 100-fold selectivity versus sst₄, respectively. SRIF and the sst₁-agonist **33** exhibit EC₅₀ values of 0.93 nM and 33 nM, respectively. Figure 3 shows that SRIF, **25** and **33** are agonists since they effectively stimulate luciferase expression in the reporter gene assay. It is noteworthy to mention that **25** is more potent than SRIF (EC₅₀: 0.37 nM versus EC₅₀: 0.93 nM), whereas the standard sst₁ agonist **33** is approximately 100-fold less potent than either of them. We have used **35**^{4,3} a short-sized somatostatin analog with no affinity to sst₁ receptors, as a negative control, in this test; it was found to be inactive at a concentration of 1 μM.

Analogue **25** was radio-iodinated with ¹²⁵I and found to bind to sections of membrane pellet of sst₁-expressing transfected cells with high specificity, as shown in Figure 5. Moreover, we evaluated the ability of the ¹²⁵I-**25** to bind to sst₁-expressing human cancers. Table 6 shows that this radioligand was able to label virtually all tested sst₁-expressing tumors, including a selection of well characterized sst₁-expressing prostate cancers, mesenchymal cancers, bronchial carcinoids and gastroenteropancreatic tumors. Figure 6 and Table 6 show that compared to the strong ¹²⁵I-[LTT]-SRIF-28 labeling, found to be fully displaceable by **33** in these tissues and therefore indicative of sst₁ expression, the ¹²⁵I-**25** labeling was noticeably weaker when performed on adjacent sections of sst₁ expressing human prostate cancer. The relatively weak ¹²⁵I-**25**-labeling is difficult to explain, since the binding affinity of the cold iodinated compound des-AA^{1,4-6,10,12,13}-[D^{nat}I¹²⁵Tyr²,DAgl(NMe,2naphthoyl)⁸,IAmp⁹]-SRIF-Thr-NH₂ (**34**) is in the low nanomolar range (IC₅₀ ≅ 1.0 nM for **34**). Sst₂-expressing tumors, used as negative controls, were completely negative for ¹²⁵I-**25** binding (Table 6), despite an extremely high density of sst₂ receptors in these tumors. This further indicates the high sst₁ specificity of the tracer.

The sst₁ pharmacophore reported previously by our group showed that the side chains of four different residues are important for the binding of these analogues.¹ They are the indole ring of DTrp at position 8, IAmp side chain at position 9, and two aromatic side chains at positions 6 or 7 and 11. The distances between the side chains of these residues should be close to the values given in Table 5.¹ In addition, the sst₁ pharmacophore was different from the other SRIF receptor pharmacophores^{63, 66, 67} in the positioning of the aromatic side chains. In all of the other SRIF receptor pharmacophores, the aromatic side chains are present at the front side of the peptide backbone, when the structure of the peptide is oriented from N- to C-terminus. In contrast, in the sst₁ pharmacophore, both of the aromatic side chains are present at the back side of the peptide backbone.¹ Therefore, any peptide that has the sst₁ pharmacophore, that involves the four residues at the proposed distance, should bind to sst₁.

To verify the identity of the sst₁ pharmacophore, the 3D structures of three analogues, **16**, **23** and **27**, that bind selectively to sst₁ with nM affinity were studied. All these analogues have IAmp at position 9, which is crucial for selectivity to sst₁. As shown in Figure 2, the other residues important for sst₁ binding, namely DTrp/DAgl⁸, Phe⁷ and Phe/Tyr¹¹ are present in all of the three analogues. The distances between the corresponding C γ atoms of the side chains of the four residues are given in Table 5. Comparing the distances with the sst₁ pharmacophore suggests that all of the three analogues have the sst₁ pharmacophore, except for a small discrepancy. But a detailed comparison of the structures show that the positioning of the side chains of the aromatic groups at position 7 and 11 is not exactly identical to that described for the sst₁ pharmacophore.¹ In the structures of the three analogues studied here, the aromatic side chains are present in the front side of the peptide backbone (Figure 2). Since these peptides have high binding affinity for sst₁, the binding of these peptides to sst₁ could be due to the inherent flexibility observed in these peptides. The presence of DAgl at position 8 introduces a large flexibility to the peptide backbone and in turn to the side chains of **23** and **27**, compared to **16** that has DTrp at position 8. This is also reflected in the number of NOEs observed for **23** and **27**, which is less compared to the number of NOEs observed for **16** (Table 3). In addition,

the chemical shift values observed for the aromatic protons of Phe⁷ and Phe¹¹ are very similar for **23** and **27** (Tables 2B, 2C) indicating a random coil or less structured elements compared to **16** (Table 2A). Comparing the chemical shift dispersion of the aromatic region of similar sst₂-selective octreotide-type SRIF analogues,⁶³ with these sst₁-selective analogues suggests that the latter are less structured in DMSO (Figure 7). Based on the conformational flexibility of **23** and **27** (Tables 2B, 2C), it is suggested that the aromatic side chains could move to the backside of the peptide backbone for sst₁ binding. The higher binding affinity of **23** and **27** compared to that of **16**, could be due to the larger flexibility of the peptide backbone of the former, resulting in a better fit of **23** and **27** into the sst₁ binding pocket compared to **16**, that shows a single conformation with much less flexibility for its peptide backbone (Figure 2A-D, Table 5).

Conclusions

To conclude, using a pharmacophore derived from the structures of undecamers,¹ we were able to design somatostatin heptamers and hexamers with improved or similar affinity and sst₁ selectivity compared to the previously published undecamers. Though the positioning of the aromatic side chains in these shortened analogues is not exactly identical to that found for the sst₁ pharmacophore proposed earlier, backbone flexibility is suggested as a mechanism for induced fit necessary for sst₁ binding.

These results demonstrate that rational and efficient SAR in peptides is possible. In this case, it was critical that the structure of the original pharmacophore be well defined and accurate. This was the case since it was based on the structures of several high affinity ligands of differing primary sequences.¹ The most potent of these sst₁-selective analogues (**25**) in respect of affinity, selectivity and functionality could be radio-iodinated. While this tracer is highly specific for labeling sst₁-expressing tumors with very high binding affinity, the sensitivity of the assay using this radioligand remains below expectations. This is somewhat disappointing, but it should be kept in mind that agonist radioligands are not devoid of caveats. We have shown previously that although ¹²⁵I-[LTT]-SRIF-28, [¹²⁵I]Tyr¹⁰-CST₁₄, or [¹²⁵I]Tyr³-octreotide are excellent radioligands showing high affinity and high specific binding in studies using membranes of recombinantly expressed SRIF receptors in CCL-39 or other cells,^{68, 69} it is clear that [¹²⁵I]Tyr¹⁰-CST₁₄ is by far inferior as a radioligand compared to ¹²⁵I-[LTT]-SRIF-28 or [¹²⁵I]Tyr³-octreotide in receptor autoradiography when using slices of brain or peripheral tissues known to express SRIF receptors,⁷⁰ illustrating the fact that all agonists are not equal.

EXPERIMENTAL PROCEDURES

Chemistry: Starting Materials

The Boc-Cys(Mob)-CM resin with a capacity of 0.3-0.5 mequiv/g was obtained according to published procedures.⁷¹ All N^α-tert-butoxycarbonyl (BOC) protected amino acids with side chain protection were purchased from Bachem Inc. (Torrance, CA), Chem-Impex Intl. (Wood Dale, IL), Novabiochem (San Diego, CA) or Reanal (Budapest, Hungary). The side chain protecting groups were as follows: Cys(Mob), Lys[Z(2Cl)] Ser(Bzl), Thr(Bzl), Tyr[Z(2Br)], and m-I-Tyr[Bzl(3Br)]. Boc-IAMP(Z),⁷² Fmoc-D/LAgl(NMe,Boc)⁴⁶ and Fmoc-D/Agl(Boc)⁷³ were synthesized in our laboratory. All reagents and solvents were reagent grade or better and used without further purification.

Peptide Synthesis

Peptides were synthesized by the solid-phase approach with Boc chemistry either manually or on a CS-Bio Peptide Synthesizer Model CS536. Boc-Cys(Mob)-CM resin with a capacity of 0.3-0.5 mequiv/g or 4-Methylbenzhydrylamine (MBHA) resin with a capacity of 0.4 mequiv/g

g was used, respectively. Couplings of the protected amino acids were mediated by diisopropylcarbodiimide (DIC) and (HOBt) in DMF for 1 h and monitored by the qualitative ninhydrin test.⁷⁴ A 3-equivalent excess of the protected amino acids based on the original substitution of the resin was used in most cases. Boc removal was achieved with trifluoroacetic acid (60% in CH₂Cl₂, 1-2% ethanedithiol or m-cresol) for 20 min. An isopropyl alcohol (1% m-cresol) wash followed TFA treatment and then successive washes with triethylamine solution (10% in CH₂Cl₂), methanol, triethylamine solution, methanol and CH₂Cl₂ completed the neutralization sequence. D/L-Agl(NMe,2naphthoyl) residue was formed on the resin. In short: After Fmoc-D/LAgl(NMe,Boc)-OH was coupled, the Boc protecting group was removed with TFA, 3-equivalent 2naphthoyl chloride and 3-equivalent DIPEA were used to acylate the free secondary amino group of the side chain. Removal of the N^α-Fmoc protecting group with 20% piperidine in DMF in two successive 5 and 15 min treatments was followed by the standard elongation protocol until the completion of the peptide.

All of the peptides were cleaved from the resin support with simultaneous side chain deprotection by anhydrous HF containing the scavengers anisole (10% v/v) and methyl sulfide (5% v/v) for 60 min at 0 °C. The diethyl ether precipitated crude peptides were cyclized in 75% acetic acid (200 mL) by addition of iodine (10% solution in methanol) until the appearance of a stable orange color. Forty minutes later, ascorbic acid was added to quench the excess iodine.

Purification and characterization of the analogues

The crude, lyophilized peptides were purified by preparative RP-HPLC⁴⁹ on a 5 cm × 30 cm cartridge, packed in the laboratory with reversed-phase Vydac C₁₈ silica (15-20 μM particle size, 300 Å) using a Waters Prep LC 4000 preparative chromatograph system, with a Waters 486 tunable absorbance UV detector and Huston Instruments Omni Scribe chart recorder. The peptides eluted with a flow rate of 100 mL/min using a linear gradient of 1% B per 3 min increase from the baseline % B. Eluent A = 0.25 N TEAP pH 2.25, eluent B = 60% CH₃CN, 40% A. As a final step, all peptides were rechromatographed in a 0.1% TFA solution and CH₃CN on the same cartridge at 100 mL/min (gradient of 1% CH₃CN/min). The collected fractions were screened by analytical RP-HPLC on a system using two Waters 501 HPLC pumps, Shimadzu SPD-6A UV detector, Rheodyne Model 7125 injector, Huston Instruments Omni Scribe chart recorder and a Vydac C₁₈ column (0.46 cm × 25 cm, 5 μm particle size, 300 Å pore size). The fractions containing the product were pooled and subjected to lyophilization. The purity of the final peptide was determined by analytical RP-HPLC performed with a linear gradient using 0.1 M TEAP pH 2.5 as eluent A and 60% CH₃CN/40% A as eluent B on a Hewlett-Packard Series II 1090 Liquid Chromatograph connected to a Vydac C₁₈ column (0.21 × 15 cm, 5 μm particle size, 300 Å pore size). The capillary zone electrophoresis (CZE) analysis of the peptides was performed on a Beckman P/ACE System 2050; field strength of 15 kV at 30 °C on an Agilent μSil bare fused-silica capillary (75 μm i.d. × 40 cm length).⁵¹ Mass spectra (MALDI-TOF-MS) were measured on an ABI-Perseptive DE-STR instrument. The instrument employs a nitrogen laser (337 nm) at a repetition rate of 20 Hz. The applied accelerating voltage was 20 kV. Spectra were recorded in delayed extraction mode (300 ns delay). All spectra were recorded in the positive reflector mode. Spectra were sums of 100 laser shots. Matrix alpha-cyano-4-hydroxycinnamic acid was prepared as saturated solutions in 0.3% TFA in 50% CH₃CN. The observed monoisotopic (M + H)⁺ values of each peptide corresponded with the calculated (M + H)⁺ values (Table 1). The diastereomers of the Agl containing peptides could be separated by preparative RP-HPLC.

Determination of the stereochemistry of Agl in the peptides

Since the L and D enantiomers of Fmoc-D/LAgl(NMe,Boc)⁴⁶ used for the synthesis of peptides (**21**, des-AA^{1,4-6,10,12,13}-[Cpa²,DCys³,LAgl(NMe,2naphthoyl)⁸]-SRIF-2Nal-NH₂ (**22**),

23-25, 27, des-AA^{1,2,4-6,10,12,13}-[LAgl(NMe,2naphthoyl)⁸,IAmp⁹,Tyr¹¹]-SRIF-NH₂ (**28**), **29**, des-AA^{1,2,4-6,10,12,13}-[DCys³,LAgl(NMe,2naphthoyl)⁸,IAmp⁹]-SRIF-2NaI-NH₂ (**30**), **31**, des-AA^{1,4-6,10,12,13}-[Tyr²,DCys³,LAgl(NMe,2naphthoyl)⁸,IAmp⁹]-SRIF-2NaI-NH₂ (**32**) were not resolved initially, two diastereomers were generated, isolated, characterized, and tested. Separation of the L- from the DAgl-containing peptides was achieved using RP-HPLC. The absolute configuration of the Agl was deduced from enzymatic hydrolysis studies with Trypsin, Aminopeptidase M and Proteinase K, (Roche Diagnostics Corp., Indianapolis, IN) respectively as we published earlier.⁵⁰ All enzymatic hydrolyses were carried out according to the protocols suggested by the manufacturers.

Trypsin, which is highly specific toward positively charged side chains with lysine and arginine, was used to determine the stereochemistry of **21** and **22**. Trypsin (Roche, 5 µg) in 0.05% TFA (20 µL) was added to peptide (0.02 µmol) dissolved in 0.046 M Tris buffer (200 µL, pH = 8.1) containing 0.01M CaCl₂. The hydrolysis was followed by RP-HPLC for 6 days. Trypsin was able to open the ring structure of **21** and **22** but the rate of reactions was very much different. We suggest that **22** contains the L-isomer of the Agl derivative and **21** contains the D-isomer of the Agl derivative because 55% of **22** versus only 28% of **21** were hydrolyzed in 6 days.

Peptides with L-amino acids at their N-terminus and IAmp at position 9 instead of Lys (**23** versus **24** and **27** versus **28**) were digested with Aminopeptidase M, which is a metalloprotease, and can hydrolyze peptides at a free α-amino group of L-amino acids (except X-Pro bonds and the amino groups of Asp, Gln or βAla), to determine the absolute configuration of Agl. The treatment of **24** and **28** with Aminopeptidase M at room temperature for 48 hours resulted in many very hydrophilic products followed by RP-HPLC, indicating that these peptides have been completely hydrolyzed, providing evidence that these analogues contained the L-enantiomer of Agl in their sequence. Compounds **23** and **27** were hydrolyzed only into two products suggesting that these two peptides contained the D-enantiomer of Agl in their sequence resulting in more resistance to the enzymatic hydrolysis. To confirm this conclusion, these analogues were also digested with Proteinase K, which is a serine protease that exhibits very broad cleavage specificity. The predominant site of cleavage is the peptide bond adjacent to the carboxyl group of hydrophobic aliphatic and aromatic amino acids with blocked alpha amino groups. Peptides were dissolved (20 µg) at a concentration of 0.3 mg/mL in 10 mM Tris buffer pH 7.8. Proteinase K (5 µL, 6 U) was added and reacted for 16 hours at 37 °C. An aliquot (5 µL) was quenched with 45 µL 0.1 N HCl prior to analysis by HPLC for determination of degradation products. The aliquots were screened using microbore RP-HPLC under buffer system A; 0.1% TFA/H₂O, buffer system B, 70% CH₃CN in A at a flow rate of 0.05 mL/min under gradient conditions 10-80% B over 30 min. Fragments of **23** identified as H-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-Cys-Thr-NH₂ and H-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-OH were confirmed by MALDI-MS. These observations verified that **23** contained the DAgl. The mass of fragments of **24** were found to be <500 Da indicating the presence of LAgl.

Analogues **25, 26, 29, 30 and 31, 32** contain a D-residue at position 2 (D-Tyr) or 3 (D-Cys), respectively, therefore enzymatic hydrolysis by Aminopeptidase M could not be expected for any of these compounds. Instead, these analogues were digested with Proteinase K as described above.

The digestion of **25** with Proteinase K for 4 days resulted in four products, which were identified as H-cyclo[Cys-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-Cys]-Thr-NH₂, H-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-Cys-Thr-NH₂, H-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-OH and the starting material H-D-Tyr-cyclo[Cys-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-Cys]-Thr-NH₂ confirmed by MALDI-MS. After the digestion of **26** with Proteinase K for 4 days no starting material was detected by HPLC, one of the fragments was identified as H-D-Tyr-Cys-Phe-Agl

(NMe,2naphthoyl)-IAmp-Phe-Cys-OH and all of the other detected fragments had a mass of less than 500 suggesting that this peptide contains the L-isomer of Agl.

The digestion of **29** with Proteinase K for 7 days resulted in three products, which were identified as H-cyclo[D-Cys-Phe-Agl(NMe,2-naphthoyl)-IAmp-Phe-Cys]-OH, H-D-Cys-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-OH and the starting material H-cyclo[D-Cys-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-Cys]-Nal-NH₂ confirmed by MALDI-MS. After the digestion of **30** with Proteinase K for 47 hours, a small amount of the starting material was detected by HPLC, and the fragments were identified as H-Agl(NMe,2naphthoyl)-IAmp-Phe-OH, H-IAmp-Phe-Cys-Nal-NH₂ confirmed by MALDI-MS suggesting that this peptide contains the L-isomer of Agl.

The digestion of **31** with Proteinase K for 47 hours resulted in three fragments, which were identified as H-cyclo[D-Cys-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-Cys]-Nal-NH₂, H-D-Cys-(Cys-Nal-NH₂)-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-OH, H-D-Cys-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-OH and the starting material confirmed by MALDI-MS. After the digestion of **32** with Proteinase K for 47 hours a small amount of the starting material was detected by HPLC, and no other fragments could be identified suggesting that this peptide contains the L-isomer of Agl.

Overall, aminoglycine-containing enantiomers were relatively easy to separate using HPLC under gradient conditions (Table 7).

NMR Experiments

The ¹H NMR spectra were recorded on a Bruker 700 MHz spectrometer operating at proton frequency of 700 MHz. Chemical shifts were measured using DMSO ($\delta = 2.49$ ppm) as an internal standard. The 2D spectra were acquired at 298 K. Resonance assignments of the various proton resonances have been carried out using total correlation spectroscopy (TOCSY),^{75, 76} double-quantum filtered spectroscopy (DQF-COSY)⁷⁷ and nuclear Overhauser enhancement spectroscopy (NOESY).⁷⁸⁻⁸⁰ The TOCSY experiments employed the MLEV-17 spin-locking sequence suggested by Davis and Bax,⁷⁵ applied for a mixing time of 50 or 70 ms. The NOESY experiments were carried out with a mixing time of 100 ms or 150 ms. The TOCSY and NOESY spectra were acquired using 800 complex data points in the ω_1 dimension and 1024 complex data points in the ω_2 dimension and were subsequently zero-filled to 1024 \times 2048 before Fourier transformation. The DQF-COSY spectra were acquired with 1024 \times 4096 data points and were zero-filled to 2048 \times 4096 before Fourier transformation. The TOCSY, DQF-COSY and NOESY spectra were acquired with 16, 16 and 24 scans, respectively, with a relaxation delay of 1 s. The signal from the residual water of the solvent was suppressed using pre-saturation during the relaxation delay and during the mixing time. The TOCSY and NOESY data were multiplied by 75° shifted sine-function in both dimensions. To differentiate exchange peaks from the NOEs, rotating frame NOESY (ROESY)^{81, 82} spectra were measured at 150, 250 and 400 msec. All spectra were processed using the software PROSA.⁸³ The spectra were analyzed using the software X-EASY.⁸⁴

Structure Determination

The chemical shift assignment of the major/minor conformer was obtained by the standard procedure using DQF-COSY and TOCSY spectra for intra-residual assignment and the NOESY spectrum was used for the sequential assignment.⁸⁵ The collection of structural restraints is based on the NOEs and vicinal ³J_{NH α couplings. Dihedral angle constraints were obtained from the ³J_{NH α couplings, which were measured from the 1D ¹H NMR spectra and from the intra-residual and sequential NOEs along with the macro GRIDSEARCH in the program CYANA.⁵³ The calibration of NOE intensities versus ¹H-¹H distance restraints and}}

appropriate pseudo-atom corrections to the non-stereo specifically assigned methylene, methyl and ring protons were performed using the program CYANA. On an average, approximately 70 NOE constraints and 15 angle constraints were utilized while calculating the conformers (Table 3). A total of 100 conformers were initially generated by CYANA and a bundle containing 20 CYANA conformers with the lowest target function values were utilized for further restrained energy minimization, using the program DISCOVER with steepest decent algorithm.⁵⁴ The resulting energy minimized bundle of 20 conformers was used as a basis for discussing the solution conformation of the different SRIF analogues. The structures were analyzed using the program MOLMOL.⁸⁶

Biology: Reagents

All reagents were of the best grade available and were purchased from common suppliers. Lactalbumin hydrolysate was from HyClone, ATP from Sigma-Aldrich, D-luciferin from Roche Diagnostics and coenzyme A from Calbiochem.

Cell lines

Chinese hamster lung fibroblasts (CCL39) stably expressing the human *sst*₁ and the luciferase reporter gene under the control of the serum response element (CCL39-*sst*₁-Luci) were from D. Hoyer (Novartis, Basel, Switzerland) and grown in DMEM with GlutaMAX-I / Ham's F-12 Nut. Mix. with GlutaMAX-I (1:1) supplemented with 10% foetal bovine serum, 100U/ml penicillin and 100 µg/ml streptomycin, and 400 µg/ml Geneticin (G418-sulfate) at 37 °C and 5% CO₂. All culture reagents were from Gibco BRL, Life Technologies.

Receptor autoradiography

Cell membrane pellets were prepared as previously described and stored at -80 °C.⁸⁷ Receptor autoradiography was performed on 20-µm thick cryostat (Microm HM 500, Walldorf, Germany) sections of the membrane pellets, mounted on microscope slides, and then stored at -20 °C. For each of the tested compounds, complete competition experiments with the universal SRIF radioligand [Leu⁸, D-Trp²², ¹²⁵I-Tyr²⁵]-SRIF-28 (¹²⁵I-[LTT]-SRIF-28) (2,000 Ci/mmol; ANAWA, Wangen, Switzerland) using 15,000 cpm/100 µL and increasing concentrations of the unlabelled peptide ranging from 0.1 - 1000 nM were performed. As control, unlabelled SRIF-28 was run in parallel using the same increasing concentrations. The sections were incubated with ¹²⁵I-[LTT]-SRIF-28 for 2 hours at room temperature in 170 mmol/L Tris-HCl buffer (pH 8.2), containing 1% BSA, 40 mg/L bacitracin, and 10 mmol/L MgCl₂ to inhibit endogenous proteases. The incubated sections were washed twice for 5 min in cold 170 mmol/L Tris-HCl (pH 8.2) containing 0.25% BSA. After a brief dip in 170 mmol/L Tris-HCl (pH 8.2), the sections were dried quickly and exposed for 1 week to Kodak BioMax MR film. IC₅₀ values were calculated after quantification of the data using a computer-assisted image processing system as described previously.⁸⁸ Tissue standards (Autoradiographic [¹²⁵I] and/or [¹⁴C] microscales, GE Healthcare; Little Chalfont, UK) that contain known amounts of isotope, cross-calibrated to tissue-equivalent ligand concentrations were used for quantification.⁸⁸⁻⁹¹

The analogue **25** was ¹²⁵I-mono-radiolabeled (2,000 Ci/mmol, ANAWA, Switzerland) and used as radioligand in binding studies on cell membrane pellet sections of cells stably expressing *sst*₁ receptors and on tissue sections, following the same protocol as described above for ¹²⁵I-[LTT]-SRIF-28.

Luciferase assay

The luciferase reporter gene assay was performed as described previously by Hoyer and colleagues^{32, 58} with minor modifications. CCL39-*sst*₁-Luci cells were seeded at 25'000 cells

per well in 96-well plates. After 24 hours, the cells were washed once with PBS and then serum-deprived for 24 hours in assay medium (DMEM with GlutaMax-I/Ham's F12 Nut. Mix. with GlutaMax-I (1:1) containing 5 g/l lactalbumin hydrolysate and 20 mM HEPES) at 37 °C and 5% CO₂. The cells were then treated in triplicate at 37 °C and 5% CO₂ with assay medium alone (basal) or with assay medium containing the compounds to be tested at concentrations between 0.1 nM and 1 μM for 5 h. The cells were then washed with PBS and lysed in lysis buffer (100 mM KPi-buffer containing 0.2% Triton X-100 and 1 mM DL-dithiothreitol). Luciferase activity was measured using a luminometer by injecting first the ATP-reagent (10 mM ATP, 35 mM glycyl-glycine and 20 mM MgCl₂, pH 7.8) and then the luciferin-reagent (0.47 mM D-luciferin, 0.27 mM coenzyme A, 35 mM glycyl-glycine and 20 mM MgCl₂, pH 7.8). Measuring parameters: delay time: 5 seconds; measurement time: 10 seconds. The 1 μM SRIF-14 effect minus the basal effect was set as 100%. Stimulation of luciferase reporter gene activity by the different compounds is expressed as % stimulation of the 1 μM SRIF-14 effect. As positive control for the luciferase reporter gene activity 10% foetal bovine serum in assay medium was used.

Acknowledgments

The project described was supported in part by Award Number 5R01DK59953-05 from the National Institute of Diabetes and Digestive and Kidney Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health. We are indebted to R. Kaiser, C. Miller for technical assistance in the synthesis and characterization of the peptides and Dr. W. Fisher, and William Low for mass spectrometric analyses. JR is the Dr. Frederik Paulsen Chair in Neurosciences Professor.

Abbreviations

The abbreviations for the common amino acids are in accordance with the recommendations of the IUPAC-IUB Joint Commission on Biochemical Nomenclature (Eur. J. Biochem. 1984, 138:9-37). The symbols represent the L-isomer except when indicated otherwise. Additional abbreviations:

AA	amino acid
Agl	aminoglycine
ATP	adenosine 5'-triphosphate
Boc	tert-butoxycarbonyl
Bzl	benzyl
Bzl(3Br)	3-bromobenzyl
cAMP	3',5'-cyclic adenosine monophosphate
Cbm	carbamoyl
CM	chloromethyl
CZE	capillary zone electrophoresis
DIC	N,N'-diisopropylcarbodiimide
DIPEA	diisopropylethylamine
DMEM	Dulbecco's modified Eagle's medium
DMF	dimethylformamide

DQF-COSY	double quantum filtered correlation spectroscopy
Fmoc	9-fluorenylmethoxycarbonyl
HEPES	4-(2-hydroxyethyl) piperazine-1-ethansulfonic acid
hhLys	homo-homo-lysine
HOBt	1-hydroxybenzotriazole
IAMP	4-(N-isopropyl)-aminomethylphenylalanine
MBHA	4-methylbenzhydramine
Mob	4-methoxybenzyl
Nal	3-(2-naphthyl)-alanine
NMP	N-methylpyrrolidinone
NOESY	nuclear Overhauser enhancement spectroscopy
PBS	phosphate buffered saline
RMSD	root mean square deviation
ROESY	rotating frame nuclear Overhauser enhancement spectroscopy
SRE	serum response element
SRIF	somatostatin
SRIF-28	somatostatin-28
sst₅	SRIF receptors
TEA	triethylamine
TEAP	triethylammonium phosphate
TFA	trifluoroacetic acid
TOCSY	total correlation spectroscopy
Z(2Br)	2-bromobenzyloxycarbonyl
Z(2Cl)	2-chlorobenzyloxycarbonyl

References

1. Grace CRR, Durrer L, Koerber SC, Erchegyi J, Reubi JC, Rivier JE, Riek R. Somatostatin receptor 1 selective analogues: 4. Three-dimensional consensus structure by NMR. *J. Med. Chem* 2005;48:523–533. [PubMed: 15658866]
2. Brazeau P, Vale WW, Burgus R, Ling N, Butcher M, Rivier JE, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science* 1973;179:77–79. [PubMed: 4682131]
3. Guillemin R, Gerich JE. Somatostatin: physiological and clinical significance. *Ann. Rev. Med* 1976;27:379–388. [PubMed: 779605]
4. Tannenbaum, GS.; Epelbaum, J. Somatostatin. In: Kostyo, JL.; Goodman, HM., editors. *Handbook of physiology - the endocrine system*. Vol. V. Oxford University Press; New York: 1999. p. 221-265. Hormonal Control of Growth

5. Janecka A, Zubrzycka M, Janecki T. Review: Somatostatin analogs. *J. Pept. Res* 2001;58:91–107. [PubMed: 11532069]
6. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. *Front. Neuroendocrinol* 2001;22:248–291. [PubMed: 11587553]
7. Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K, Hoyer D. Drug design at peptide receptors: somatostatin receptor ligands. *J. Mol. Neurosci* 2002;18:15–27. [PubMed: 11931345]
8. Hoyer, D.; Epelbaum, J.; Feniuk, W.; Humphrey, PPA.; Meyerhof, W.; O'Carroll, AM.; Patl, Y.; Reisine, T.; Reubi, JC.; Schindler, M.; Schonbrunn, A.; Taylor, JE.; Vezzani, A. Somatostatin receptors. In: Girdlestrom, D., editor. *The IUPHAR compendium of receptor characterization and classification*. Vol. 2 ed.. IUPHAR Media; London: 2000. p. 354-364.
9. Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. *Neuropeptides* 2001;35:1–23. [PubMed: 11346306]
10. Patel YC. Somatostatin and its receptor family. *Front. Neuroendocrinol* 1999;20:157–198. [PubMed: 10433861]
11. Siehler S, Hoyer D. Characterisation of human recombinant somatostatin receptors. 4 Modulation of phospholipase C activity. *Naunyn-Schmiedeberg's Arch Pharmacol* 1999;360:522–532.
12. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester H-J, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC. Internalization of sst₂, sst₃ and sst₅ receptors: Effects of somatostatin agonist and antagonists. *J. Nucl. Med* 2006;47:502–511. [PubMed: 16513620]
13. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Erchegyi J, Rivier J, Mäcke HR, Reubi JC. Radiolabeled somatostatin receptor antagonists are preferable to agonists for *in vivo* peptide receptor targeting of tumors. *Proc. Natl. Acad. Sci. USA* 2006;103:16436–16441. [PubMed: 17056720]
14. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W. Regulation and function of somatostatin receptors. *J. Neurochem* 2004;89:1057–91. [PubMed: 15147500]
15. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. *Nat. Rev. Drug Discov* 2003;2:999–1017. [PubMed: 14654798]
16. Piwko C, Thoss VS, Schubach E, Kummer J, Langenegger D, Probst A, Hoyer D. Pharmacological characterisation of human cerebral cortex somatostatin SRIF1 and SRIF2 receptors. *Naunyn Schmiedeberg's Arch Pharmacol* 1997;355:161–167. [PubMed: 9050007]
17. Thermos K. Functional mapping of somatostatin receptors in the retina: a review. *Vision Res* 2003;43:1805–1815. [PubMed: 12826104]
18. Bocci G, Culler MD, Fioravanti A, Orlandi P, Fasciani A, Colucci R, Taylor JE, Sadat D, Danesi R, Del Tacca M. In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. *Eur. J. Clin. Invest* 2007;37:700–708. [PubMed: 17696959]
19. Reubi JC, Schaer JC, Waser B, Hoeger C, Rivier J. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. *Eur. J. Pharmacol* 1998;345:103–110. [PubMed: 9593601]
20. Reubi JC, Waser B, Laissue JA, Gebbers JO. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. *Cancer Res* 1996;56:1922–1931. [PubMed: 8620515]
21. Reubi JC, Waser B, Schaer J-C, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. *European Journal of Nuclear Medicine* 2001;28:836–846. [PubMed: 11504080]
22. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 mRNAs in primary human tumors using *in situ* hybridization. *Cancer Res* 1994;54:3455–3459. [PubMed: 8012966]
23. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. *J. Clin. Endocrinol. Metab* 1995;80:2806–2814. [PubMed: 7673428]
24. Müller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. *J. Clin. Endocrinol. Metab* 1995;80:1386–1392. [PubMed: 7714115]

25. Lanneau C, Bluet-Pajot MT, Zizzari P, Csaba Z, Dournaud P, Helboe L, Hoyer D, Pellegrini E, Tannenbaum GS, Epelbaum J, Gardette R. Involvement of the Sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: an in vitro and in vivo antisense study. *Endocrinology* 2000;141:967–979. [PubMed: 10698172]
26. Kreienkamp H-J, Akgün E, Baumeister H, Meyerhof W, Richter D. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. *FEBS Lett* 1999;462:464–466. [PubMed: 10622746]
27. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. *J. Clin. Endocrinol. Metab* 2003;88:2797–2802. [PubMed: 12788890]
28. Vasilaki A, Papisava D, Hoyer D, Thermos K. The somatostatin receptor (sst(1)) modulates the release of somatostatin in the nucleus accumbens of the rat. *Neuropharmacology* 2004;47:612–618. [PubMed: 15380378]
29. Dal Monte MD, Petrucci C, Vasilaki A, Cervia D, Grouselle D, Epelbaum J, Kreienkamp HJ, Richter D, Hoyer D, Bagnoli P. Genetic deletion of somatostatin receptor 1 alters somatostatinergetic transmission in the mouse retina. *Neuropharmacology* 2003;45:1080–1092. [PubMed: 14614951]
30. Thermos K, Bagnoli P, Epelbaum J, Hoyer D. The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina? *Pharmacol. Ther* 2006;110:455–464. [PubMed: 16274747]
31. Hoyer D, Dixon K, Gentsch C, Vassout A, Enz A, Jaton A, Nunn C, Schoeffter P, Neumann P, Troxler T, Pfaeffli P. NVP-SRA880, a somatostatin sst₁ receptor antagonist promotes social interactions, reduces aggressive behaviour and stimulates learning. *The Pharmacologist* 2002;44:A254.
32. Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, Langenegger D, Bouhelal R, Hurth K, Neumann P, Troxler T, Pfaeffli P. SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. *Neurosci. Lett* 2004;361:132–5. [PubMed: 15135911]
33. Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. *Neuroendocrinology* 2004;79:142–148. [PubMed: 15103227]
34. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. *Biochem. Biophys. Res. Commun* 2002;297:828–834. [PubMed: 12359227]
35. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Rosa Pelizzo M, Culler MD, Degli Uberti EC. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. *J. Clin. Endocrinol. Metab.* 2006
36. Liapakis G, Hoeger C, Rivier J, Reisine T. Development of a selective agonist at the somatostatin receptor subtype SSTR1. *Journal of Pharmacology and Experimental Therapeutics* 1996;276:1089–1094. [PubMed: 8786539]
37. Rivier JE, Hoeger C, Erchegyi J, Gulyas J, DeBoard R, Craig AG, Koerber SC, Wenger S, Waser B, Schaer J-C, Reubi JC. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). *J. Med. Chem* 2001;44:2238–2246. [PubMed: 11405660]
38. Rivier JE, Kirby DA, Erchegyi J, Waser B, Eltschinger V, Cescato R, Reubi JC. Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. *J. Med. Chem* 2005;48:515–522. [PubMed: 15658865]
39. Erchegyi J, Hoeger CA, Low W, Hoyer D, Waser B, Eltschinger V, Schaer J-C, Cescato R, Reubi JC, Rivier JE. Somatostatin receptor 1 selective analogues: 2. N-methylated scan. *J. Med. Chem* 2005;48:507–514. [PubMed: 15658864]
40. Erchegyi, J.; Hoeger, C.; Wenger, S.; Waser, B.; Schaer, J-C.; Reubi, J-C.; Rivier, JE. In: Lebl, M.; Houghten, R.A., editors. N-methyl scan of a sst1-selective somatostatin (SRIF) analog; Peptides - The wave of the future: 2nd International Peptide Symposium/17th American Peptide Symposium; San Diego, CA. June 10-14, 2001; 2001. p. 719-720. American Peptide Symposium: San Diego, CA, 2001

41. Jiang G, Miller C, Koerber SC, Porter J, Craig AG, Bhattacharjee S, Kraft P, Burris TP, Campen CA, Rivier CL, Rivier JE. Betidamino acid scan of the GnRH antagonist Acyline. *J. Med. Chem* 1997;40:3739–3748. [PubMed: 9371239]
42. Cervini L, Theobald P, Corrigan A, Craig AG, Rivier C, Vale W, Rivier J. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser⁷ substitutions. *J. Med. Chem* 1999;42:761–768. [PubMed: 10052982]
43. Reubi JC, Schaer J-C, Wenger S, Hoeger C, Erchegyi J, Waser B, Rivier J. SST3-selective potent peptidic somatostatin receptor antagonists. *Proc. Natl. Acad. Sci. USA* 2000;97:13973–13978. [PubMed: 11095748]
44. Erchegyi, J.; Wenger, S.; Waser, B.; Eltschinger, V.; Cescato, R.; Reubi, JC.; Koerber, SC.; Grace, RCR.; Riek, R.; Rivier, JE. In: Blondelle, SE., editor. *Use of betidamino acids in drug design; Understanding Biology Using Peptides, The 19th American Peptide Symposium*; San Diego, CA. June 18–23, 2005; 2005. p. 517–518. American Peptide Society: San Diego, CA, 2005
45. Qasmi D, René L, Badet B. An α -aminoglycine derivative suitable for solid phase peptide synthesis using Fmoc strategy. *Tetrahedron Letters* 1993;34:3861–3862.
46. Jiang G-C, Simon L, Rivier JE. Orthogonally protected *N*-methyl-substituted α -aminoglycines. *Prot. Pep. Lett* 1996;3:219–224.
47. Rivier JE, Jiang G-C, Koerber SC, Porter J, Craig AG, Hoeger C. Betidamino acids: Versatile and constrained scaffolds for drug discovery. *Proc. Natl. Acad. Sci. USA* 1996;93:2031–2036. [PubMed: 8700880]
48. Hoeger CA, Galyean RF, Boublik J, McClintock RA, Rivier JE. Preparative reversed phase high performance liquid chromatography. II. Effects of buffer pH on the purification of synthetic peptides. *Biochromatography* 1987;2:134–142.
49. Miller C, Rivier J. Peptide chemistry: Development of high-performance liquid chromatography and capillary zone electrophoresis. *Biopolymers Pept. Sci* 1996;40:265–317.
50. Rivier J, Erchegyi J, Hoeger C, Miller C, Low W, Wenger S, Waser B, Schaer J-C, Reubi JC. Novel sst₄-selective somatostatin (SRIF) agonists. Part I: Lead identification using a betide scan. *J. Med. Chem* 2003;46:5579–5586. [PubMed: 14667212]
51. Miller C, Rivier J. Analysis of synthetic peptides by capillary zone electrophoresis in organic/aqueous buffers. *J. Pept. Res* 1998;51:444–451. [PubMed: 9650719]
52. Gairi M, Saiz P, Madurga S, Roig X, Erchegyi J, Koerber SC, Reubi JC, Rivier JE, Giralt E. Conformational analysis of a potent SSTR3-selective somatostatin analogue by NMR in water solution. *J. Peptide Sci* 2006;12:82–91. [PubMed: 16365912]
53. Güntert P, Mumenthaler C, Wüthrich K. Torsion angle dynamics for NMR structure calculation with the new program DYANA. *J. Mol. Biol* 1997;273:283–298. [PubMed: 9367762]
54. Hagler, AT. Theoretical simulation of conformation, energetics and dynamics of peptides. In: Udenfriend, S.; Meienhofer, J.; Hruby, VJ., editors. *The Peptides: Analysis, Synthesis, Biology*. Vol. 7. Academic Press; Orlando, FL: 1985. p. 213–299.
55. Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE, Reubi JC. Design and *in vitro* characterization of highly sst₂-selective somatostatin antagonists suitable for radio-targeting. *J. Med. Chem* 2008;51:4030–4037. [PubMed: 18543899]
56. Hill CS, Treisman R. Differential activation of c-fos promoter elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors. *Embo J* 1995;14:5037–5047. [PubMed: 7588632]
57. Treisman R. Journey to the surface of the cell: Fos regulation and the SRE. *EMBO J* 1995;14:4905–4913. [PubMed: 7588619]
58. Nunn C, Cervia D, Langenegger D, Tenaillon L, Bouhelal R, Hoyer D. Comparison of functional profiles at human recombinant somatostatin sst₂ receptor: simultaneous determination of intracellular Ca²⁺ and luciferase expression in CHO-K1 cells. *Br. J. Pharmacol* 2004;142:150–160. [PubMed: 15037513]
59. Reubi JC, Schaer J-C, Waser B, Hoeger C, Rivier J. A selective analog for the somatostatin sst₁-receptor subtype expressed by human tumors. *Eur. J. Pharmacol* 1998;345:103–110. [PubMed: 9593601]
60. Hocart SJ, Jain R, Murphy WA, Taylor JE, Coy DH. Highly potent cyclic disulfide antagonists of somatostatin. *J. Med. Chem* 1999;42:1863–1871. [PubMed: 10354394]

61. Hocart SJ, Jain R, Murphy WA, Taylor JE, Morgan B, Coy DH. Potent antagonists of somatostatin: Synthesis and biology. *J. Med. Chem* 1998;41:1146–1154. [PubMed: 9544214]
62. Melacini G, Zhu Q, Osapay G, Goodman M. A refined model for the somatostatin pharmacophore: Conformational analysis of lanthionine-sandostatin analogs. *J. Med. Chem* 1997;40:2252–2258. [PubMed: 9216844]
63. Grace CRR, Erchegyi J, Koerber SC, Reubi JC, Rivier J, Riek R. Novel sst₂-selective somatostatin agonists. Three-dimensional consensus structure by NMR. *J. Med. Chem* 2006;49:4487–4496. [PubMed: 16854054]
64. Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, Hadcock JR. Identification and characterization of novel somatostatin antagonists. *Mol. Pharmacol* 1996;50:709–715. [PubMed: 8863814]
65. Bass, RT.; Buckwalter, BL.; Patel, BP.; Pausch, MH.; Price, LA.; Strnad, J.; Hadcock, JR. *Mol. Pharmacol.* Vol. 51. 1997. Identification and characterization of novel somatostatin antagonists; p. 170Erratum
66. Grace CRR, Erchegyi J, Koerber SC, Reubi JC, Rivier J, Riek R. Novel sst₄-selective somatostatin (SRIF) agonists. Part IV: Three-dimensional consensus structure by NMR. *J. Med. Chem* 2003;46:5606–5618. [PubMed: 14667215]
67. Grace CRR, Erchegyi J, Reubi JC, Rivier JE, Riek R. Three-dimensional consensus of structure of sst₂-selective somatostatin (SRIF) antagonists by NMR. *Biopolymers*. 2008in press
68. Siehler S, Seuwen K, Hoyer D. [¹²⁵I]Tyr¹⁰-cortistatin¹⁴ labels all five somatostatin receptors. *Naunyn Schmiedebergs Arch Pharmacol* 1998;357:483–489. [PubMed: 9650799]
69. Siehler S, Seuwen K, Hoyer D. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. *Naunyn Schmiedebergs Arch Pharmacol* 1999;360:488–499. [PubMed: 10598788]
70. Fehlmann D, Langenegger D, Schuepbach E, Siehler S, Feuerbach D, Hoyer D. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery. *J. Physiol. (Paris)* 2000;94:265–281. [PubMed: 11088004]
71. Horiki K, Igano K, Inouye K. Amino acids and peptides. Part 6. Synthesis of the Merrifield resin esters of N-protected amino acids with the aid of hydrogen bonding. *Chem. Lett* 1978;2:165–168.
72. Rivier JE, Jiang G, Porter J, Hoeger C, Craig AG, Corrigan AZ, Vale WW, Rivier CL. GnRH antagonists: novel members of the azaline B family. *J. Med. Chem* 1995;38:2649–2662. [PubMed: 7629804]
73. Sypniewski M, Penke B, Simon L, Rivier J. (R)-tert-Butoxycarbonylamino-fluorenylmethoxycarbonyl-glycine from (S)-Benzyloxycarbonyl-serine or from papain resolution of the corresponding amide or methyl ester. *J. Org. Chem* 2000;65:6595–6600. [PubMed: 11052107]
74. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. *Anal. Biochem* 1970;34:595–598. [PubMed: 5443684]
75. Davis DG, Bax A. Assignment of complex ¹H NMR spectra via two-dimensional homonuclear Hartmann-Hahn spectroscopy. *J. Am. Chem. Soc* 1985;107:2820–2821.
76. Braunschweiler L, Ernst RR. Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy. *J. Magn. Reson* 1983;53:521–528.
77. Rance M, Sorensen OW, Bodenhausen B, Wagner G, Ernst RR, Wüthrich K. Improved spectral resolution in COSY 1H NMR spectra of proteins via double quantum filtering. *Biochem. Biophys. Res. Commun* 1983;117:479–485. [PubMed: 6661238]
78. Kumar A, Wagner G, Ernst RR, Wüthrich K. Buildup rates of the nuclear Overhauser effect measured by two-dimensional proton magnetic resonance spectroscopy: Implications for studies of protein conformation. *J. Am. Chem. Soc* 1981;103:3654–3658.
79. Macura S, Ernst RR. Elucidation of cross-relaxation in liquids by two-dimensional NMR spectroscopy. *Mol. Phys* 1980;41:95–117.
80. Macura S, Huang Y, Suter D, Ernst RR. Two-dimensional chemical exchange and cross-relaxation spectroscopy of coupled nuclear spins. *J. Magn. Reson* 1981;43:259–281.
81. Bax A, Davis DG. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. *J. Magn. Reson* 1985;65:355–360.

82. Bothner-By AA, Stephens RL, Lee J, Warren CD, Jeanloz RW. Structure determination of a tetrasaccharide: transient nuclear Overhauser effects in the rotating frame. *J. Am. Chem. Soc* 1984;106:811–813.
83. Güntert P, Dotsch V, Wider G, Wüthrich K. Processing of multi-dimensional NMR data with the new software PROSA. *J. Biomol. NMR* 1992;2:619–629.
84. Eccles C, Güntert P, Billeter M, Wüthrich K. Efficient analysis of protein 2D NMR spectra using the software package EASY. *J. Biomol. NMR* 1991;1:111–130. [PubMed: 1726780]
85. Wüthrich, K. *NMR of Proteins and Nucleic Acids*. J. Wiley & Sons; New York: 1986.
86. Koradi R, Billeter M. MOLMOL: a program for display and analysis of macromolecular structures. *PDB Newsletter* 1998;84:5–7.
87. Reubi JC, Schaer JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. *European Journal of Nuclear Medicine* 2000;27:273–282. [PubMed: 10774879]
88. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. *Cancer Res* 1990;50:5969–5977. [PubMed: 2168286]
89. Reubi JC. *In vitro* identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. *J. Nucl. Med* 1995;36:1846–1853. [PubMed: 7562054]
90. Baskin DG, Wimpy TH. Calibration of [¹⁴C]plastic standards for quantitative autoradiography of [¹²⁵I]labeled ligands with Amersham Hyperfilm beta-max. *Neurosci. Lett* 1989;104:171–177. [PubMed: 2812531]
91. Miller JA, Zahniser NR. The use of ¹⁴C-labeled tissue paste standards for the calibration of ¹²⁵I-labeled ligands in quantitative autoradiography. *Neurosci. Lett* 1987;81:345–350. [PubMed: 3431749]




Figure 1. Survey of characteristic NOEs describing the secondary structure of analogues (A) **16**, (B) **23** and (C) **27**. Thin, medium and thick bars represent weak (4.5-6 Å), medium (3-4.5 Å) and strong (< 3 Å) NOEs observed in the NOESY spectrum. One letter code represents the amino acids in the sequence of the peptide, where f, g, w and X represents DPhe, DAgl(NMe, 2naphthoyl), DTrp and IAmp.




Figure 2.

3D NMR structures of analogues (A) H-DPhe-c[Cys-Phe-DTrp-IAmp-Phe-Cys]-Thr-NH₂ (**16**), (B) H-c[Cys-Phe-DAgl(NMe,2naphthoyl)-IAmp-Phe-Cys]-Thr-NH₂ (**23**) and (C) H-c[Cys-Phe-DAgl(NMe,2naphthoyl)-IAmp-Tyr-Cys]-NH₂ (**27**). For each analogue, 20 energy-minimized conformers with the lowest target function are used to represent the 3D NMR structure. The bundle is obtained by overlapping the C^α atoms of all the residues. The backbone and the side chains are displayed including the disulphide bridge. The amino acid side chains that are proposed to be involved in sst₁ binding are highlighted: light green, DTrp/DAgl at position 8; blue, IAmP at position 9; yellow, Phe at positions 7 and 11. In (D) the side chains of sst₁ binding analogue **5** (in dark green) are superimposed on the structure of **16** (in grey), **23** (in cyan) and **27** (in magenta). It should be noted that the aromatic side chains at position 7 and 11 of analogue **5** are in the other side of the peptide backbone compared to **16**, **23** and **27**.




Figure 3. The SRIF analogue **25** is a potent $ss1$ agonist when tested in the luciferase reporter gene assay. The assay was performed as described in Materials and Methods. CCL39- $ss1$ -Luci cells were treated with increasing concentrations (0.1 nmol/L, 1 nmol/L, 10 nmol/L, 100 nmol/L, and 1 μ mol/mL) of SRIF (●), **33** (■), or **25** (◆). The stimulation of the luciferase reporter gene activity by the compounds is expressed as % stimulation of the 1 μ mol/mL SRIF effect. Shown are the dose-response curves of the compounds. The $ss3$ -antagonist **35** (▲), used as negative control at 1 μ mol/mL, shows no effect in the luciferase reporter gene assay.




Figure 4. Schematic drawings of agonist pharmacophores for receptor-selective analogues binding to the somatostatin receptors: (A) *sst*₁, (B) *sst*₂, (C) *sst*_{2/5} and (D) *sst*₄. The amino acid side chains, which are part of the pharmacophores and the range of distances between the corresponding C_γ atoms of the side chains are shown.




Figure 5. ^{125}I -**25** specifically labels the sst₁ expressing cell line. Autoradiograms showing total binding of ^{125}I -**25** in sst₁ (A), sst₂ (C), sst₃ (E), sst₄ (G), and sst₅ (I) receptor expressing cells. Only sst₁ cells are labeled. Autoradiograms showing non-specific binding of ^{125}I -**25** in sst₁ (B), sst₂ (D), sst₃ (F), sst₄ (H), and sst₅ (J) receptor expressing cells (in the presence of an excess of unlabeled **25**).




Figure 6. ^{125}I -**25** labels an sst_1 receptor-expressing human prostate cancer. (A) Hematoxylin eosin stained tumor section (bar: 1 mm). (B, C) Autoradiograms showing total binding of ^{125}I -[LTT]-SRIF-28 with strong tumor labeling (B) that is displaceable by the sst_1 -selective **33** (C) indicating sst_1 expression. (D,E,F) Autoradiograms showing total binding of ^{125}I -**25** with clear tumor labeling (D) that is displaceable by an excess of unlabeled **25** (E) or **33** (F).




Figure 7. Amide and aromatic region of the 1D proton NMR spectra of analogues des-AA^{1,4-6,11-13}-[DPhe², DTrp⁸]-SRIF-Thr-NH₂ (octreotide amide) (**11**), **16**, **23** and **27**. The chemical shift dispersion of the aromatic region of analogs **11** and **16** are comparable, while that of **23** and **27** suggests that these peptides are less structured in DMSO compared to analogues **11** and **16**.

Table 1

Physico-chemical properties and sst₁₋₅ binding affinities (IC₅₀s, nM) of sst₁₋₅ selective analogues and control peptides

Compound	Purity (%)	MS ^c		IC ₅₀ nM ^d					Luciferase Assay		
		HPLC ^a /CZE ^b /MS ^c	(mono) calcd.	MH ⁺ (mono) obs.	sst ₁	sst ₂	sst ₃	sst ₄		sst ₅	
1	SRIE-28	98	93	1636.72	1637.70	2.9 ± 0.2	2.6 ± 0.11	4.3 ± 0.39	2.9 ± 0.2	2.9 ± 0.24	agonist
2	des-AA ^{1,2,5} -[DTTP ⁸ ,IAmp ⁹]-SRIE ³⁶	94	97	1484.66	1485.5	31 ± 13	>IK	540; 150	>1000	>IK	>IK
3	des-AA ^{1,2,5} -[DTTP ⁸ ,IAmp ⁹ ,Tyr ¹¹]-SRIE ³⁷	98	97	1500.66	1501.5	17 ± 6.0	>IK	>IK	>IK	>IK	>IK
4	des-AA ^{1,2,5} -[DTTP ⁸ ,IAmp ⁹ ,ITyr ¹¹]-SRIE ³⁷	94	96	1626.55	1627.5	3.6 ± 0.69	>IK	>IK	>IK	>IK	>IK
5	des-AA ^{1,2,5} -[DTTP ⁸ ,IAmp ⁹ ,ITyr ¹¹]-Cbm-SRIE ¹	91	97	1669.56	1670.56	2.3 ± 0.2	>IK	618 ± 125	>IK	>IK	>IK
6	des-AA ^{1,2,5} -cvelo(7-12)[Glu ¹ ,DTTP ⁸ ,IAmp ⁹ ,ITyr ¹¹ ,hhLys ¹²]-SRIE ³⁸	98	98	1645.57	1646.50	6.1 ± 0.6	>IK	>IK	>IK	>IK	>IK
7	des-AA ^{1,2,5} -[DAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹ ,Tyr ¹¹]-SRIE ³⁹	95	93	1554.67	1555.70	3.3 ± 1.0	>IK	>IK	562 ± 135	>IK	>IK
8	des-AA ^{1,2,4,5,12,13} -[DTTP ⁸ ,SRIE ⁴⁰]	95	98	1078.45	1078.90	27 ± 3.4	41 ± 8.7	13 ± 3.2	1.8 ± 0.7	46 ± 27	>IK
9	des-AA ^{1,2,4,5,12,13} -[DTTP ⁸ ,IAmp ⁹]-SRIE	98	98	1168.58	1169.5	>IK	>IK	>IK	>IK	>IK	>IK
10	des-AA ^{1,2,5,12,13} -[DTTP ⁸ ,IAmp ⁹]-SRIE	99	99	1296.58	1297.1	189 ± 31	>IK	789 ± 231	932 ± 125	>IK	>IK
11	des-AA ^{1,4,6,11,15} -[DPhe ² ,DTTP ⁸]-SRIE-Thr-NH ₂	95	99	1031.4	1032.0	>IK	1.9 ± 0.33	39 ± 14	>IK	5.1 ± 1.1	>IK
12	des-AA ^{1,4,6,11,13} -[Cpa ² ,DCys ³ ,Tyr ¹¹ ,DTTP ⁸]-SRIE-2Nal-NH ₂ ⁶⁰	99	99	1177.43	1178.43	>IK	5.7 ± 1.5	112 ± 32	296 ± 19	218 ± 63	>IK
13	des-AA ^{1,4,6,11,13} -[Cpa ² ,DCys ³ ,Tyr ¹¹ ,DTTP ⁸ ,IAmp ⁹]-SRIE-2Nal-NH ₂	98	98	1267.48	1268.45	>IK	240; 665	300; 234	>IK	>IK	>IK
14	des-AA ^{1,4,6,10,12,13} -[Tyr ² ,DTTP ⁸ ,IAmp ⁹]-SRIE-Thr-NH ₂	98	98	1284.55	1285.6	150; 186	>IK	60; 284	>IK	>IK	>IK
15	des-AA ^{1,2,4,6,10,12,13} -[DTTP ⁸ ,IAmp ⁹]-SRIE-Thr-NH ₂	99	99	1020.45	1021.51	108; 120	>IK	>IK	585; 250	>IK	>IK
16	des-AA ^{1,4,6,10,12,13} -[DPhe ² ,DTTP ⁸ ,IAmp ⁹]-SRIE-Thr-NH ₂	99	99	1167.50	1168.38	41; 14	>IK	448; 72	1349; 252	>IK	>IK
17	des-AA ^{1,2,4,6,10,12,13} -[DTTP ⁸ ,IAmp ⁹ ,ITyr ¹¹]-SRIE-Thr-NH ₂	99	99	1162.33	1163.24	591; 889	>IK	701; 989	468; 1273	>IK	>IK
18	des-AA ^{1,4,6,10,12,13} -[DPhe ² ,DTTP ⁸ ,IAmp ⁹ ,ITyr ¹¹]-SRIE-Thr-NH ₂	99	98	1309.40	1310.43	449; 565	>IK	514; 864	>IK	>IK	>IK
19	des-AA ^{1,2,4,6,10,12,13} -[DCys ³ ,DTTP ⁸ ,IAmp ⁹ ,ITyr ¹¹]-SRIE-2Nal-NH ₂	97	98	1258.36	1259.33	356; 689	>IK	162; 438	329; 489	>IK	>IK
20	des-AA ^{1,4,6,10,12,13} -[Cpa ² ,DCys ³ ,DTTP ⁸ ,IAmp ⁹ ,ITyr ¹¹]-SRIE-2Nal-NH ₂	95	95	1439.39	1440.21	>IK	>IK	>IK	>IK	>IK	>IK
21	des-AA ^{1,4,6,10,12,13} -[Cpa ² ,DCys ³ ,DAg(NMe,2naphthoyl) ⁸]-SRIE-2Nal-NH ₂	98	96	1262.46	1262.3	20; 29	100; 881	17; 23	71; 72	9.9; 29	>IK
22	des-AA ^{1,4,6,10,12,13} -[Cpa ² ,DCys ³ ,LAg(NMe,2naphthoyl) ⁸]-SRIE-2Nal-NH ₂	91	93	1262.46	1262.3	>IK	>IK	312	>IK	>IK	>IK
23	des-AA ^{1,2,4,6,10,12,13} -[DAAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-Thr-NH ₂	94	95	1074.45	1075.60	1.0 ± 0.25	>IK	681 ± 52	95 ± 18	>IK	agonist
24	des-AA ^{1,2,4,6,10,12,13} -[LAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-Thr-NH ₂	97	98	1074.45	1075.59	37; 42	>IK	848; 253	833; 525	>IK	>IK
25	des-AA ^{1,4,6,10,12,13} -[DTyr ² ,DAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-Thr-NH ₂	99	99	1237.52	1238.52	0.19 ± 0.04	>IK	158 ± 14	27 ± 7.5	>IK	agonist
26	des-AA ^{1,4,6,10,12,13} -[DTyr ² ,LAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-Thr-NH ₂	99	99	1237.52	1238.25	124; 97	>IK	>IK	>IK	>IK	>IK
27	des-AA ^{1,2,4,6,10,12,13} -[DAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹ ,Tyr ¹¹]-SRIE-NH ₂	80	87	989.40	990.18	4.7; 7.3	>IK	252; 381	695; 266	>IK	agonist
28	des-AA ^{1,2,4,6,10,12,13} -[LAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹ ,Tyr ¹¹]-SRIE-NH ₂	81	94	989.40	990.18	530; 631	>IK	>IK	>IK	>IK	>IK
29	des-AA ^{1,2,4,6,10,12,13} -[DCys ³ ,DAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-2Nal-NH ₂	91	93	1170.48	1171.70	1.2 ± 0.54	>IK	112 ± 23	63 ± 32	181 ± 5	agonist
30	des-AA ^{1,2,4,6,10,12,13} -[DCys ³ ,LAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-2Nal-NH ₂	98	85	1170.48	1171.50	267; 316	>IK	329; 729	535; 214	279; 635	>IK
31	des-AA ^{1,4,6,10,12,13} -[Tyr ² ,DCys ³ ,DAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-2Nal-NH ₂	81	87	1333.55	1334.81	8.2 ± 4.9	>IK	410 ± 114	270 ± 122	>IK	agonist
32	des-AA ^{1,4,6,10,12,13} -[Tyr ² ,DCys ³ ,LAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-2Nal-NH ₂	73	86	1333.55	1334.61	189; 365	>IK	463; 1169	>IK	>IK	>IK
33	des-AA ^{1,5} -[Tyr ² ,DTTP ⁸ ,IAmp ⁹]-SRIE ³⁷	97	97	1647.73	1648.8	14 ± 3	>IK	>IK	>IK	>IK	agonist
34	des-AA ^{1,4,6,10,12,13} -[D ¹⁰⁰ ITyr ² ,DAg(NMe,2naphthoyl) ⁸ ,IAmp ⁹]-SRIE-Thr-NH ₂	88	99	1363.41	1364.29	0.8 ± 0.14	>IK	344 ± 123	45 ± 6.7	>IK	>IK

Legend **Table 1**: Structure of SRIE: (Cyclo 3-14)H-Ala¹-Gly²-Cys³-Lys⁴-Asn⁵-Phe⁶-Tyr⁷-Trp⁸-Lys⁹-Thr¹⁰-Phe¹¹-Thr¹²-Ser¹³-Cys¹⁴-OH

^a Percent purity determined by HPLC using buffer system: A = TEAP (pH 2.5) and B = 60% CH₃CN/40% A with a gradient slope of 0.2 mL/min on a Vydac C18 column (0.21 × 15 cm, 5-µm particle size, 300 Å pore size). Detection at 214 nm.

^b Capillary zone electrophoresis (CZE) was done using a Beckman P/ACE System 2050 controlled by an IBM Personal System/2 Model 50Z and using a ChromJet integrator. Field strength of 15 kV at 30 °C, mobile phase: 100 mM sodium phosphate (85:15, H₂O:CH₃CN) pH 2.50, on a Supelco P175 capillary (363 µm OD × 75 µm ID × 50 cm length). Detection at 214 nm.

^c The calculated m/z of the monoisotope compared with the observed [M + H]⁺ monoisotopic mass.

^dThe IC₅₀ values (in nM) were derived from competitive radioligand displacement assays reflecting the affinities of the analogues for the five cloned somatostatin receptors using the non-selective [¹²⁵I]-[Leu⁸,DTrp²²,Tyr²⁵]SRIF-28 as radioligand. Mean value ± SEM when n ≥ 3. When n < 3, individual values of two assays are listed. 1K corresponds to 1000.

Table 2A
Chemical shifts (in ppm) of 16 in DMSO-d₆

Residue	NH	α H	β H	Others
D ² Phe	8.00	4.19	3.26, 2.97	OD: 7.40, QE: 7.36
Cys ³	9.28	5.39	2.88, 2.76	
Phe ⁷	8.55	4.71	2.87, 2.76	OD: 6.99, QE: 7.03
D ⁸ Trp	8.66	4.23	2.66, 2.50	HD1: 6.86, HE3: 7.49, HE1: 10.73 HZ3: 7.04, HZ2: 7.36, HH2: 7.11
I ⁹ Amp	8.88	4.24	3.09, 2.56	QD: 7.29, QE: 7.36, QT: 4.06, HH: 8.59, OK1: 1.15, OK2: 1.15, HI: 3.15
Phe ¹¹	7.72	4.90	3.19, 3.00	OD: 7.30, QE: 7.20
Cys ¹⁴	8.65	5.20	2.84, 2.84	
Thr ¹⁵	8.11	4.25	4.05	γ CH ₃ : 1.07, OH: 5.21
NH ₂	7.58, 7.39			

Table 2B

Chemical shifts (in ppm) of 23 in DMSO-d₆

Residue	Conf	NH	αH	βH	Others
Cys ³	Major		4.01	3.07, 2.89	
	Minor				
Phe ⁷	Major	8.87	5.03	3.01, 2.91	OD: 7.28, OE: 7.17
	Minor		4.75		
DAl ⁸	Major	8.80	6.53		QG: 2.27, H1: 7.78, H3: 7.65, H4: 8.02 H5: 8.01, H6: 7.65, H7: 8.02, H8: 7.25
	Minor	9.21	5.74		QG: 2.55, H1: 7.86, H3: 7.69, H4: 7.93 H5: 7.92, H6: 7.69, H7: 7.93, H8: 7.36
IAmp ⁹	Major	8.24	4.27	2.92, 2.80	OD: 7.12, OE: 7.21, QT: 3.78, HH: 7.37, OK1: 1.23, OK2: 1.10, HI: 3.04
	Minor		-		OE: 7.36, OT: 4.06, HI: 3.24
Phe ¹¹	Major	8.39	4.57	3.21, 2.93	OD: 7.29, OE: 7.21
	Minor	8.12	4.48		
Cys ¹⁴	Major	7.81	4.63	3.07, 2.83	
	Minor	8.12	4.55		
Thr ¹⁵	Major	7.67	4.10	4.04	γCH ₃ : 1.03, OH: 4.90
	Minor	7.60			
NH ₂			7.17, 7.29		

Table 2C

Chemical shifts (in ppm) of 27 in DMSO-d₆

Residue	Conf	NH	αH	βH	Others
Cys ³	Major		3.95	3.03, 2.82	
	Minor				
Phe ⁷	Major	8.75	5.02	3.01, 2.91	QD: 7.28, OE: 7.41
	Minor		4.75	3.00, 2.87	
DArg ⁸	Major	8.86	6.53		QG: 2.34, H1: 7.81, H3: 7.62, H4: 8.00 H5: 7.89, H6: 7.64, H7: 8.00, H8: 7.28
	Minor	9.23	5.71		QG: 2.62, H5: 8.01
IAmp ⁹	Major	8.35	4.24	2.83, 2.83	QD: 7.10, OE: 7.21, OT: 3.81, HH: 7.34, QK1: 1.23, QK2: 1.11, HI: 3.07
	Minor		-		HH: 7.21, OT: 4.07, HI: 3.23
Tyr ¹¹	Major	8.30	4.41	3.08, 2.83	QD: 7.07, OE: 6.69
	Minor	8.02	4.35		QD: 7.27
Cys ¹⁴	Major	7.62	4.41	3.02, 2.80	
	Minor				
NH ₂	Major	7.27, 7.08			

Table 3
Characterization of the NMR structures of the analogues studied by NMR^a

Parameters	16	23	27
Restrains			
NOE Distances	93	72	58
Angles	23	16	7
CYANA Target function	0.29	0.25	0.27
RMSD (in Å)			
Backbone	0.35 ± 0.15	0.75 ± 0.18	0.12 ± 0.06
Overall	1.12 ± 0.20	1.47 ± 0.31	1.92 ± 0.37
Residual Violations on			
Distances			
No ≥ 0.1 Å	0.50 ± 0.20	0.20 ± 0.06	0.40 ± 0.08
Max (Å)	0.80 ± 0.15	0.06 ± 0.02	0.08 ± 0.01
Dihedral Angles			
No ≥ 1.5°	0.0 ± 0.01	0.0 ± 0.0	0.0 ± 0.0
Max (°)	0.1 ± 0.10	0.0 ± 0.0	0.0 ± 0.0
CFF91 energies (kcal/mol)			
Total energy	218 ± 9	233 ± 8	202 ± 4
Van der Waals	168 ± 8	181 ± 5	174 ± 6
Electro-static	50 ± 7	51 ± 4	28 ± 2

Table 4
Torsion angles ϕ , ψ and χ_1 (in degrees) of the bundle of 20 energy minimized conformers

Analogue	Angle	D ^{Phe} ²	Cys ³	Phe ⁷	D ^{Trp} ⁸	I ^{Amp} ⁹	Phe ¹¹	Cys ¹⁴	Thr ¹⁵
16	ϕ	-	-174 ± 5	-108 ± 12	60 ± 7	63 ± 1	-68 ± 11	52 ± 34	-54 ± 75
	ψ	-147 ± 1	46 ± 2	145 ± 5	31 ± 4	14 ± 2	-68 ± 24	100 ± 18	134 ± 47
	χ_1	9 ± 30	-125 ± 11	1 ± 32	27 ± 31	-109 ± 1	-168 ± 19	-100 ± 37	102 ± 76
23					D^{Arg}⁸				
	ϕ	-	-	-84 ± 62	-13 ± 62	-117 ± 33	48 ± 7	-96 ± 26	146 ± 64
	ψ		179 ± 60	170 ± 10	-74 ± 13	-158 ± 11	26 ± 2	-172 ± 2	-98 ± 81
χ_1		99 ± 61	-41 ± 50	-59 ± 93	-150 ± 6	-155 ± 4	-102 ± 12	-137 ± 40	
27					D^{Arg}⁸		Tyr¹¹		
	ϕ	-	-	-156 ± 8	95 ± 4	166 ± 3	-110 ± 8	-57 ± 6	
	ψ		132 ± 9	157 ± 1	-54 ± 1	42 ± 1	-35 ± 3	-85 ± 0	
χ_1		34 ± 13	27 ± 1	-112 ± 102	-18 ± 80	-18 ± 80	141 ± 9	-109 ± 0	

Table 5

Distances between C_γ atoms (in Å) of selected residues for the analogues studied by NMR and the sst₁/sst₄- pharmacophores

	F ⁷ - X ⁸ F ⁷	I-Amp ⁹ F ⁷ - I-Amp ⁹ F ⁷	F ⁷ - F ¹¹ X ⁸	I-Amp ⁹ X ⁸ - F ¹¹ X ⁸	F ⁷ - F ¹¹ X ⁸	I-Amp ⁹ F ⁷ - F ¹¹ X ⁸
Sst ₁ pharmacophore	6.0-7.5	9.0-11.0	6.0-7.5	7.0-8.0	9.5-12.0	8.0-10.0
Sst ₄ pharmacophore	-	-	-	4.5-6.5	5.5-9.5	4.5-6.5
16	5.9-7.0	9.4-9.8	5.1-6.8	5.3-6.7	8.2-8.8	8.0-8.6
23	5.9-7.8	7.3-10.6	6.6-11.0	6.9-8.1	9.6-11.2	5.8-6.6
27	5.2-6.8	8.5-10.0	6.4-7.7	4.5-7.1	9.0-9.8	6.4-8.3

X refers to either DTrp or DAGl(NMe, 2naphthoyl) residues.

Table 6

¹²⁵I-25 specifically labels sst1-expressing human cancers

Tumor type	# of cases	¹²⁵ I-[LTT]-SRIF-28 binding displaceable by 33		¹²⁵ I-25 binding displaceable by 33	
		Incidence	Density	Incidence	Density
A: Sst1-expressing tumors					
- Prostate Cancer	8	8/8	+++	7/8	+
- Mesenchymal Tumors	7	7/7	++ / +++	6/7	++
- Bronchial Carcinoids	6	6/6	++	6/6	+/+++
- Gastroenteropancreatic Tumors	4	4/4	++	4/4	+/+++
B: Sst2-expressing tumors	8	0/8*	-	0/8	-

+++ , ++ , + means high, moderate or low receptor density, respectively.

* ¹²⁵I-[LTT]-SRIF-28-binding in these tumors is fully displaceable by octreotide.

Table 7
Separation of the D- from the L-Agl-containing peptides by RP-HPLC

Compound	HPLC-Column	Gradient	Retention time (min)
21	Vydac C ₁₈	20 to 80% B in 40 min	32.33
22	Vydac C ₁₈	20 to 80% B in 40 min	35.26
23	Vydac C ₁₈	30 to 60% B in 30 min	17.93
24	Vydac C ₁₈	30 to 60% B in 30 min	23.39
25	Gemini C ₁₈	20 to 60% B in 40 min	30.56
26	Gemini C ₁₈	20 to 60% B in 40 min	34.15
27	Vydac C ₁₈	30 to 70% B in 30 min	11.75
28	Vydac C ₁₈	30 to 70% B in 30 min	14.91
29	Gemini C ₁₈	40 to 70% B in 30 min	20.28
30	Gemini C ₁₈	40 to 70% B in 30 min	25.10
31	Vydac C ₁₈	30 to 70% B in 40 min	27.68
32	Vydac C ₁₈	30 to 70% B in 40 min	32.75

HPLC buffer system: A = TEAP (pH 2.5) and B = 60% CH₃CN/40% A with a gradient slope of 1% B/min, at flow rate of 0.2 mL/min.